Niagen Bioscience Inc
NASDAQ:NAGE · NASDAQ Capital Market
+$0.02 today
Vol 0.57M · Avg 0.97M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:NAGE · Revenue to Net Income
Key Ratios
Analysis
$130.4M of revenue converted into $18.6M of net income for the selected period. Gross margin is 64.3% and net margin is 14.3%, showing how much revenue survives after costs and taxes. EPS is $0.22, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $129.4M +29.9% | $99.6M +19.2% | $83.6M +16.0% | $72.0M +6.8% | $67.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $46.2M +21.6% | $38.0M +15.9% | $32.8M +12.1% | $29.3M +12.7% | $26.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $83.2M +35.1% | $61.6M +21.3% | $50.8M +18.7% | $42.8M +3.2% | $41.5M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 64.3% +2.4pp | 61.8% +1.1pp | 60.8% +1.4pp | 59.4% -2.1pp | 61.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $6.3M +5.2% | $6.0M +21.3% | $5.0M +2.7% | $4.8M +25.9% | $3.8M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $62.6M +30.8% | $47.8M -7.0% | $51.4M -9.1% | $56.6M -12.6% | $64.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $68.9M +27.9% | $53.9M -4.5% | $56.4M -8.2% | $61.4M -10.4% | $68.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.4M -2.3% | $1.5M -13.0% | $1.7M -9.5% | $1.9M +15.9% | $1.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | $19.6M +90.0% | $10.3M +419.8% | -$3.2M +77.9% | -$14.7M +42.4% | -$25.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 15.2% +4.8pp | 10.4% +14.2pp | -3.9% +16.5pp | -20.3% +17.4pp | -37.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | $14.3M +85.0% | $7.7M +238.0% | -$5.6M +69.9% | -$18.6M +31.2% | -$27.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 11.0% +3.3pp | 7.8% +14.5pp | -6.7% +19.2pp | -25.9% +14.3pp | -40.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.1M +88.4% | $1.1M +70.8% | $661.0K +21933.3% | $3.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 -100.0% | $55.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $3.9M +245.1% | $1.1M +70.8% | $661.0K -68.3% | $2.1M +3896.4% | -$55.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $18.2M +105.4% | $8.9M +279.3% | -$4.9M +70.1% | -$16.5M +39.0% | -$27.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 14.1% +5.2pp | 8.9% +14.8pp | -5.9% +17.0pp | -23.0% +17.3pp | -40.2% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $810.0K +165.6% | $305.0K | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | $17.4M +103.3% | $8.6M +273.1% | -$4.9M +70.1% | -$16.5M +39.0% | -$27.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | 13.4% +4.8pp | 8.6% +14.5pp | -5.9% +17.0pp | -23.0% +17.3pp | -40.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +120.0% | $0 +242.9% | -$0 +70.8% | -$0 +40.0% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +81.8% | $0 +266.9% | -$0 +72.5% | -$0 +40.0% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $79.2M -7.3% | $85.4M +21.1% | $70.5M +2.4% | $68.9M +2.6% | $67.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $85.4M +7.2% | $79.7M +6.3% | $75.0M +7.5% | $69.7M +3.8% | $67.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
$747.81M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Keros Therapeutics, Inc.
NASDAQ:KROS
$324.78M
Akebia Therapeutics, Inc.
NASDAQ:AKBA
$248.00M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NAGE generate?
Niagen Bioscience Inc (NAGE) reported $129.42M of revenue in fiscal 2025.
Is NAGE profitable?
Niagen Bioscience Inc (NAGE) reported $17.38M of net income, with a net margin of 13.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.